MARKET

MNMD

MNMD

MIND MEDICINE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.510
+0.200
+6.04%
After Hours: 3.640 +0.13 +3.70% 19:59 05/18 EDT
OPEN
3.320
PREV CLOSE
3.310
HIGH
3.550
LOW
3.160
VOLUME
8.63M
TURNOVER
--
52 WEEK HIGH
5.77
52 WEEK LOW
0.2911
MARKET CAP
1.20B
P/E (TTM)
-20.1261
1D
5D
1M
3M
1Y
5Y
Wall Street Unicorns in Process of Changing the Healthcare Landscape
, /PRNewswire/ -- Before 1970, promising research was being conducted on the potential therapeutic effects of a broad category of psychedelic drug compounds, including substances such as psilocybin, DMT (dimethyltryptamine), LSD (lysergic acid diethylamid...
PR Newswire - PRF · 12h ago
MindMed Stock Moves Higher After Finalizing Generalized Anxiety Disorder As Initial Indication For LSD Trial
Benzinga · 1d ago
Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021.
Benzinga · 1d ago
MindMed on track for Q3 IND submission for LSD as anxiety treatment; shares up 14%
MindMed (MNMD) is on track for a Q3 submission of an IND for LSD as a treatment for Generalized Anxiety Disorder ("GAD").The company recently received Type C Meeting responses from
Seekingalpha · 1d ago
MindMed Receives FDA Type C Meeting Response For Project Lucy Phase 2b Clinical Trial; Co. Says On Target To Submit IND Application In Q3
MindMed (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announces receipt of Type C Meeting Responses from FDA leading to the finalization of the Company's clinical
Benzinga · 1d ago
MindMed Selects Generalized Anxiety Disorder as Initial Indication in Drug Development Program; Shares Rise
MT Newswires · 1d ago
Compass Pathways Shares See Volume; Marijuana Moment Reports 'FDA Clears Researchers To Study MDMA Use By Therapists Being Trained In Psychedelic Medicine'
https://www.marijuanamoment.net/fda-clears-researchers-to-study-mdma-use-by-therapists-being-trained-in-psychedelic-medicine/
Benzinga · 4d ago
Mind Medicine reports Q1 results
Mind Medicine (MNMD): Q1 Net and comprehensive loss of $14MTotal assets as of March 31, 2021 were $201M, including $160M in cash.Press Release
Seekingalpha · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MNMD. Analyze the recent business situations of MIND MEDICINE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MNMD stock price target is 4.144 with a high estimate of 4.144 and a low estimate of 4.144.
EPS
Institutional Holdings
Institutions: 7
Institutional Holdings: 218.69K
% Owned: 0.06%
Shares Outstanding: 340.67M
TypeInstitutionsShares
Increased
1
8.00K
New
3
31.00K
Decreased
1
2.25K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
  • All
  • Financials
  • Insiders
No Data
About MNMD
Mind Medicine (MindMed) Inc., formerly Broadway Gold Mining Ltd., is a neuro-pharmaceutical company. The Company discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering. The Company addresses the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine.

Webull offers kinds of Mind Medicine (MindMed) Inc stock information, including NASDAQ:MNMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNMD stock methods without spending real money on the virtual paper trading platform.